Your Dividend's Quiet Irish Backer: What the US-Ireland 'Partnership' Really Is

On St. Patrick's Day 2026, with the Taoiseach in the Oval Office, the story Washington and Dublin wanted told was a love story. Ireland was touting a record of cumulative investment in the United States and more than 200,000 American jobs; Micheál Martin called the relationship "very, very much mutually beneficial." US and Ireland, the refrain goes, do very well together.

They do — but not in the direction those announcements suggest. The relationship that actually shows up in your brokerage account runs the other way, and it is far bigger than the Irish side of the ledger.

The $300 billion that moves the other way

Here is the asymmetry nobody at the press conference mentioned. US multinationals booked just under $300 billion in profits in Ireland last year — more than in any country this side of their own. The flow is so concentrated that American companies pay roughly three-quarters of all corporate tax collected in Ireland. Ireland's boom is not mostly an Irish-American success story; it is a tax story with an Irish mailing address.

Why would a US company put profits in Dublin? Because of how corporate tax works. Ireland's headline rate has long been far below the US federal 21% — historically 12.5%, now 15% for large firms — and certain royalty and intellectual-property income is taxed as low as 6.25%. Book your patent royalties in Dublin, sell the product in the US, and a meaningful share of your earnings avoids the higher US rate. This is legal and broadly OECD-sanctioned, and it is why Ireland leads the world in corporate profit shifting.

For a dividend investor, the interesting part is who does this and what it does to their numbers. American pharma, in particular, reports most of its profit offshore while booking little or none in the US — even though the US is where the revenue comes from. Merck reported a $5 billion loss in the United States but $26 billion of profit abroad. AbbVie reported a $3.5 billion US loss and $10 billion abroad. In a typical year the largest US drugmakers set aside almost nothing to cover US income tax on current earnings.

Where your dividend sits in that stack

Now connect that to the payout. Dividends are paid out of after-tax earnings and free cash flow — the money left over. Every dollar of profit a company keeps out of the 21% US net is a dollar that flows into the pool from which it funds and grows its dividend. So the Irish arrangement is not a curiosity for the tax department; it is part of the earnings machinery behind some of the best-known income stocks in the market.

Take Merck, which has paid a dividend for about two dozen years and yields roughly 2.3% today. Its cash flow — $16 billion in free cash flow over the trailing year — is real, and that is what secures the payout, not Ireland. But its earnings and thus its ability to keep growing that dividend are riding, in part, on a tax rate that is structurally lower than America's. Same for AbbVie and much of the sector.

The contrast that should sharpen your judgment is Pfizer, yielding about 6.2% and paying out more than 100% of trailing earnings as a dividend. A yield that high is not a gift. It is partly the market telling you it doubts the cushion behind the payout — doubts that do not go away because a low effective tax rate supports the book profit. When a dividend yield looks too good to be true, check whether the cash flow and the tax structure can actually fund it over a cycle. Ireland does not fix an uncovered dividend.

A cushion a policy change can remove

Here is the risk that makes all of this investable rather than trivia. This tax cushion is an arrangement, not a moat. The same political forces that smiled through the March meeting have also called Ireland a "tax scam", slapped tariffs on Irish goods, and pressed a global push to raise rates up to through a top-up tax. US pharma already faces a potential tariff-related cost bump on shipments home. If effective taxes rise — whether through the global minimum tax, transfer-pricing enforcement, or tariffs — the after-tax cash that funds dividend growth across the sector thins. The profits are real, but the tax rate on them is a policy variable with a calendar attached to it.

That does not make every US company with an Irish entity a sell, or a buy. "Doing very well together" is, for a shareholder, a measure of how much of a company's earnings quietly depend on where its intellectual property is booked. The income investor's job is not to take a position on Ireland; it is to know the difference between a dividend grounded in free cash flow and pricing power, and one that leans on a tax structure that an unhappy administration could unwind. Merck's payout survives the tax conversation because it is backed by cash. Pfizer's high yield does not escape scrutiny just because the profit is booked in Dublin.

Before you buy any healthy-looking yield, ask who is standing behind it — and whether that benefactor can be removed by a signature. The US-Ireland friendship is real, friendly, and, for the companies that fund your income, quietly tax-subsidized. Treat the subsidy as real, and treat it as impermanent.